Novo Nordisk Reduces Weight-Loss Drug Wegovy Price by Upto 37% in India

Danish pharmaceutical giant Novo Nordisk has reduced the price of its blockbuster obesity drug Wegovy in India by as much as 37%. According to Reuters, the drugmaker has reduced the price of its blockbuster treatment by up to 33%, according to a company document shared with its distributors. 

This move comes amid intense competition from Mounjaro maker Eli Lilly and a strategy to expand in one of the world’s fastest-growing obesity treatment markets. 

Key Pricing Change & Competitive Context

The revised pricing sets the highest weekly dose of 2.4 mg at ₹16,400 (approx.$186.59), down from around ₹24,389.06. The lowest 0.25 mg dose has been cut to ₹10,850 from roughly ₹16,260.94. 

The adjustment follows Wegovy’s launch in India in June and coincides with the upcoming patent expiry of its active ingredient, semaglutide, in March 2026. 

Implications for Market & Patients

For Novo Nordisk, the price cut signals a strategic push to stay competitive in India’s GLP-1 obesity market, estimated to reach billions globally by decade’s end. For patients, the reduction improves the affordability of one of the leading injectable treatments, potentially widening access. 

The move also raises pressure on pricing models and may accelerate the entry of generics once patent protections end. This reduction incorporates the impact of a September revision to the national sales tax structure, which independently lowered the drug's cost slightly.

Read More: India Deep Tech Alliance to Invest up to $15 Million in AI, Space, and Defence Startups!

Conclusion

With Wegovy’s price trimmed by one-third in India, Novo Nordisk is recalibrating its market strategy to contend with rival drugs and upcoming generic competition. How the change impacts uptake, market share, and overall industry pricing dynamics will guide the next phase of obesity treatment rollout in India.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.